NCI COMPASS-Comprehensive Oncologic Molecular Pathology and Sequencing Service

分子诊断科是目前唯一的CLIA和美国病理学院批准的临床实验室，在NCI认证下对来自NIH患者的病理材料进行分子肿瘤学检测。新建立的COMPASS项目旨在扩展下一代测序，以支持CCR的临床和研究。在2022财年（2021年7月至2022年6月），NGS实验室运行1376 TSO500，全外显子组测序和RNA外显子组测序测试。这些结果为NCI的75个临床方案和NIAID、NIAMS、NIDDK、NHGRI的9个方案提供了精确病理诊断和精确肿瘤学支持，包括CCR罕见肿瘤、肝脏和前列腺癌登月项目。我们也在CCR校内诊所筛选NCI-MATCH患者的靶点。该项目还开发并部署了全外显子组测序，RNA外显子组测序分析在2022财年用于临床服务。全基因组测序用于临床和研究，特别是支持CCR罕见肿瘤、肝癌和前列腺癌登月计划。无细胞循环DNA NGS检测仍在开发中。COMPASS计划通过举办每周一次的NGS技术评审会议、每周一次的分子病理学/神经肿瘤学会议和每周一次的分子病理学/儿科肿瘤学会议，讨论分子发现、治疗以及特定患者或突变，为病理学和肿瘤学团队，特别是下一代病理学家和内科科学家提供了培训或继续教育的绝佳机会。

The Molecular Diagnostics Section is currently the only CLIA and College of American Pathology approved clinical laboratory within the NCI certified for performing molecular oncology testing on pathology materials from NIH patients. The newly established COMPASS program is to expand next generation sequencing to support clinical and research in CCR. In FY22 (July 2021 - June 2022), the NGS lab run 1376 TSO500, whole exome sequencing, and RNA exome sequencing tests. These results have provided support of precision pathological diagnosis and precision oncology for 75 clinical protocols from NCI and 9 protocol from NIAID, NIAMS, NIDDK, NHGRI including CCR Rare Tumor, Liver and Prostate Cancer Moonshot projects. We are also screening the targets in patients from CCR intramural clinics for NCI-MATCH. The program also developed and deployed whole exome sequencing, RNA exome sequencing assays into clinical service during FY22. The whole genome sequencing is in use for clinical and research especially for supporting CCR Rare Tumor, Liver and Prostate Cancer Moonshot projects. The cell-free circulating DNA NGS assay is still in development. The COMPASS program provided the great opportunities of training or continuing education for both pathology and oncology teams especially next generation of pathologists and physician scientists by running weekly NGS technical review conference, weekly molecular pathology/neuro-oncology conference, and weekly molecular pathology/pediatric oncology conference to discuss molecular finding, treatment, and beyond particular patient or mutation.